Literature DB >> 33052422

Intensive care accessibility and outcomes in pandemics.

Fernando G Zampieri1, Markus B Skrifvars2, James Anstey3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33052422      PMCID: PMC7556548          DOI: 10.1007/s00134-020-06264-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Limited access to intensive care units (ICU) during pandemics can be a contributor to excessive mortality. While lots of attention is given to individual ICU’s performance focusing on staffing, organizational features and adherence to best care management protocols [1, 2], there are few discussions as to how to optimize access to ICU at a regional level taking into account population densities [3]. Such efforts could theoretically result in a more homogeneous distribution of patients and a lower risk of overloading units in a given geographical area. In this issue of Intensive Care Medicine, Bauer and coworkers provide an in-depth study of accessibility to ICU beds in 14 European countries during the coronavirus disease 2019 (COVID-19) pandemic [4]. They demonstrate that great variability exists in geographical access to intensive care in different European countries, and also imply that this may be associated with case fatality ratio (CFR) from COVID-19 (that is, the ratio of deaths due to COVID-19 to the number of COVID-19 cases during a given time). Any attempt to provide clear data on this question is to be commended. There are, however, many challenges to such efforts that are recognized and discussed by the authors. First, there is currently no uniform definition of what constitutes an ICU bed [5]. Some authors suggest that this requires the immediate availability of mechanical ventilation within the ward in question, but this definition is by no means universally accepted. Second, it is hard to define “accessibility” where multiple models of health care coexist. For example, in countries with mixed public–private models (such as Brazil or Australia), it is commonplace to have an empty private ICU bed a few 100 m from patients in need of ICU care inside a public hospital (or even inside another private hospital with fewer resources). The scarcity of data in low-income countries also precludes similar analysis [6]. In this sense, European countries that have strong public health-care systems and lower social inequalities may represent the best model to evaluate how ease of access is related to outcome. The authors quite reasonably chose a pragmatic method to address the first issue: using the local definition of an ICU. For the second issue, they measured accessibility in terms of a regional ratio of hospital beds to 100,000 population (accessibility index, AI) and the distance to the closest hospital providing intensive care. While imperfect, this definition captures two important factors influencing access to a resource: how available the resource is, and how far away it is. First, by using detailed geographical information, the authors concluded that there were large differences between the participating countries, with some having a more homogeneous AI and others a lower AI, with poorly covered areas speckled across the country. Germany, Estonia and Austria had the greatest AI, while Sweden and Denmark had the lowest AI values. Bauer et al. also looked at the association between AI as a marker of ICU access and COVID-19 CFR in countries where data were available. The authors correlated the estimated AI with CRF using the same dataset and concluded that an association exists between AI and CRF for the included countries. If there were a causal relationship, this would be of great importance, but solid conclusions are difficult to make based on an association alone. It is also unclear whether COVID-19 is a highly time-critical condition like cardiac arrest or major trauma where urgent ICU intervention is required [7]. Furthermore, case fatality rate is simply the ratio between the number of deaths due to one disease to the number of cases of the disease actually diagnosed. Only under very special circumstances could CFR be considered a perfect proxy of quality of care: for example, in a hypothetical scenario where two almost identical populations (with regards to risk factors) were fully tested for a disease but cared for in different settings. In all other situations, the association between CFR and AI should be considered speculative, since several major factors influence CFR (Fig. 1). The list displayed in Fig. 1 is non-exhaustive, as many other variables, including economical background, race, gender, etc., could also influence access to health care. Finally, case fatality rate can be low simply due to more testing (and greater detection of milder cases) or due to local differences in attributing the cause of death to the disease (for example, unexpected deaths at home may be considered related to the pandemic or not).
Fig. 1

The complex pathway between access to health care and case report fatality in a directed acyclic graph (DAG). Biasing paths are shown in red and causal paths in green. Minimal sufficient adjustment sets for estimating the total effect of access to health care on CFR include two possible scenarios: (1) adjusted for age, comorbidities, cultural factors/end-of-life preferences, gender/race, number of cases, and socioeconomic factors or (2) age, comorbidities, gender/race, population density, and socioeconomic factors. This DAG was made with dagitty R package [15]. Code is provided in the appendix. As all DAGs, items not included are assumed to not be on the causal pathway. For example, socioeconomic factors are not a single value, but a constellation of several other determinants which may be hard to measure. Therefore, the DAG is likely incomplete. CFR case fatality rate. The play symbol (Access to Healthcare box) means that is the exposure of interest. The dash (CFR box) is for mentioning which is the outcome of interest

The complex pathway between access to health care and case report fatality in a directed acyclic graph (DAG). Biasing paths are shown in red and causal paths in green. Minimal sufficient adjustment sets for estimating the total effect of access to health care on CFR include two possible scenarios: (1) adjusted for age, comorbidities, cultural factors/end-of-life preferences, gender/race, number of cases, and socioeconomic factors or (2) age, comorbidities, gender/race, population density, and socioeconomic factors. This DAG was made with dagitty R package [15]. Code is provided in the appendix. As all DAGs, items not included are assumed to not be on the causal pathway. For example, socioeconomic factors are not a single value, but a constellation of several other determinants which may be hard to measure. Therefore, the DAG is likely incomplete. CFR case fatality rate. The play symbol (Access to Healthcare box) means that is the exposure of interest. The dash (CFR box) is for mentioning which is the outcome of interest Different approaches could have been more informative, but would have required more extensive collection of patient-level data. Ideally, one would aim to estimate the proportion of COVID-19 deaths that are directly caused by poor accessibility issues [8, 9]. This would represent the population attributable fraction of mortality [10]. This would require data including, but not restricted to, age, comorbidities and other known risk factors for COVID-19. Another approach would be to simply consider the excess deaths that occurred during the pandemic in the regional areas when compared with previous years and their association with AI [11]. While excess deaths also has shortcomings, it may better reflect the impact of the pandemic on the health-care system and its ability to cope with excess cases. The main advantage of using excess deaths between years for the same country is to indirectly control for other, hard-to-measure confounders which are intrinsically tied to cultural aspects, such as end-of-life care or priorities for ICU admissions. In brief, the paper by Bauer et al. provides important data on ICU accessibility over several European countries. While the understanding that ICU access is heterogeneous in Europe is not entirely new [12, 13], they are of great importance during the current and possible future pandemics [14]. If differences in accessibility to ICU care indeed really influence COVID-19-related mortality, this has major ramifications, but this needs to be verified in future studies with more detailed patient-level data. Below is the link to the electronic supplementary material. Supplementary file1 (ODT 6 kb)
  15 in total

1.  Robust causal inference using directed acyclic graphs: the R package 'dagitty'.

Authors:  Johannes Textor; Benito van der Zander; Mark S Gilthorpe; Maciej Liskiewicz; George Th Ellison
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

Review 2.  The ABCDEF Bundle in Critical Care.

Authors:  Annachiara Marra; E Wesley Ely; Pratik P Pandharipande; Mayur B Patel
Journal:  Crit Care Clin       Date:  2017-04       Impact factor: 3.598

Review 3.  The present and future of cardiac arrest care: international experts reach out to caregivers and healthcare authorities.

Authors:  Jerry P Nolan; Robert A Berg; Clifton W Callaway; Laurie J Morrison; Vinay Nadkarni; Gavin D Perkins; Claudio Sandroni; Markus B Skrifvars; Jasmeet Soar; Kjetil Sunde; Alain Cariou
Journal:  Intensive Care Med       Date:  2018-06-02       Impact factor: 17.440

4.  Triaging patients to the ICU: a pilot study of factors influencing admission decisions and patient outcomes.

Authors:  Maité Garrouste-Orgeas; Luc Montuclard; Jean-François Timsit; Benoit Misset; Marie Christias; Jean Carlet
Journal:  Intensive Care Med       Date:  2003-04-02       Impact factor: 17.440

5.  Refusal of intensive care unit admission due to a full unit: impact on mortality.

Authors:  René Robert; Jean Reignier; Caroline Tournoux-Facon; Thierry Boulain; Olivier Lesieur; Valérie Gissot; Vincent Souday; Mouldi Hamrouni; Cécile Chapon; Jean-Paul Gouello
Journal:  Am J Respir Crit Care Med       Date:  2012-02-16       Impact factor: 21.405

6.  Survival of critically ill patients hospitalized in and out of intensive care units under paucity of intensive care unit beds.

Authors:  Elisheva Simchen; Charles L Sprung; Noya Galai; Yana Zitser-Gurevich; Yaron Bar-Lavi; Gabriel Gurman; Moti Klein; Amiram Lev; Leon Levi; Fabio Zveibil; Micha Mandel; George Mnatzaganian
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

Review 7.  International comparisons of intensive care: informing outcomes and improving standards.

Authors:  Meghan Prin; Hannah Wunsch
Journal:  Curr Opin Crit Care       Date:  2012-12       Impact factor: 3.687

8.  Implications of ICU triage decisions on patient mortality: a cost-effectiveness analysis.

Authors:  David L Edbrooke; Cosetta Minelli; Gary H Mills; Gaetano Iapichino; Angelo Pezzi; Davide Corbella; Philip Jacobs; Anne Lippert; Joergen Wiis; Antonio Pesenti; Nicolo Patroniti; Romain Pirracchio; Didier Payen; Gabriel Gurman; Jan Bakker; Jozef Kesecioglu; Chris Hargreaves; Simon L Cohen; Mario Baras; Antonio Artigas; Charles L Sprung
Journal:  Crit Care       Date:  2011-02-09       Impact factor: 9.097

9.  Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries.

Authors:  Margaret E Kruk; Anna D Gage; Naima T Joseph; Goodarz Danaei; Sebastián García-Saisó; Joshua A Salomon
Journal:  Lancet       Date:  2018-09-05       Impact factor: 79.321

Review 10.  Critical care and the global burden of critical illness in adults.

Authors:  Neill K J Adhikari; Robert A Fowler; Satish Bhagwanjee; Gordon D Rubenfeld
Journal:  Lancet       Date:  2010-10-11       Impact factor: 79.321

View more
  1 in total

1.  Identifying areas of potential critical healthcare shortages: A case study of spatial accessibility to ICU beds during the COVID-19 pandemic in Florida.

Authors:  Kyusik Kim; Mahyar Ghorbanzadeh; Mark W Horner; Eren Erman Ozguven
Journal:  Transp Policy (Oxf)       Date:  2021-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.